Collection of Samples and Clinical Data From Patients With Amyloid Diseases

Study Overview
=================
Brief Summary
-----------------
RATIONALE: Collecting and storing samples of blood, urine, tissue and data from patients with amyloid diseases to test in the laboratory may help the study of this disease in the future. PURPOSE: This research study is collecting samples from patients with amyloid diseases

Detailed Description
-----------------
OBJECTIVES: To establish and maintain a database of clinical material (i.e., blood, urine, and tissue) and information on patients with amyloid diseases. OUTLINE: Blood, urine, tissue, and bone marrow samples are collected during standard laboratory evaluations to maintain a repository of biospecimens in the Gerry Amyloid Research Laboratory, to permit the correlation of clinical results with measured biological events, and for future research studies. Bone marrow RNA samples are examined for immunoglobulin light-chain gene sequences and amino acids by polymerase chain reaction and positional cloning. Blood serum and urine samples are evaluated for amyloid protein stability by high-resolution calorimetry, isothermal-titration calorimetry, and far- and near-UV circular dichroism and fluorescence spectroscopy. Urine samples are also examined for post-translational modifications (e.g., glycosylation, sulfation, and cross-linking) to identify common features unique to amyloid proteins. Tissue samples are analyzed for biochemical and biophysical properties and for post-translational modifications in light chains. Quality of life is assessed by the 36-Item Short Form Survey (SF-36).

Official Title
-----------------
Data, Tissue, Blood, and Urine Repository for Amyloid Diseases

Conditions
-----------------
Multiple Myeloma

Intervention / Treatment
-----------------
* Genetic: clonality analysis
* Genetic: polymerase chain reaction
* Genetic: protein analysis
* Other: biologic sample preservation procedure
* Other: laboratory biomarker analysis
* Procedure: fluorescence spectroscopy
* Procedure: quality-of-life assessment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: DISEASE CHARACTERISTICS: Diagnosis or suspicion of amyloidosis PATIENT CHARACTERISTICS: Referred to the Amyloid Treatment and Research Center at Boston University Medical Center PRIOR CONCURRENT THERAPY: Not specified Exclusion Criteria: None

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Genetic: clonality analysis|analyze clonality|
|Genetic: polymerase chain reaction|analyze polymerase chain reaction|
|Genetic: protein analysis|analyze protein|
|Other: biologic sample preservation procedure|preserve biologic samples|
|Other: laboratory biomarker analysis|analyze laboratory biomarkers|
|Procedure: fluorescence spectroscopy|perform fluorescence spectroscopy on specimens|
|Procedure: quality-of-life assessment|assess quality of life at each follow-up for life|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Establish a repository to promote biochemical research |  | life of study | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Collection of clinical material and information |  | life of study | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
primary systemic amyloidosis